Celularity (CELUW) Income from Continuing Operations (2019 - 2025)
Celularity (CELUW) reported Income from Continuing Operations of 24359000.0 for Q4 2025, down 83.25% year-over-year from 145399275.71 in Q4 2024, and down 5.56% quarter-over-quarter from 23076000.0 in Q3 2025.
Celularity (CELUW) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Celularity (CELUW) has 7 years of Income from Continuing Operations data on file, last reported at 24359000.0 in Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 24359000.0, down 83.25% year-over-year; the trailing twelve-month figure through Dec 2025 was 91713000.0 (down 58.42% YoY), and the FY2025 annual result was 91716000.0, down 58.43% from the prior year.
- Income from Continuing Operations declined to 24359000.0 in Q4 2025 per CELUW's latest filing, from 23076000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 49938000.0 in Q3 2021 and troughed at 93876000.0 in Q3 2023.
- A 5-year average of 21591300.0 and a median of 20883500.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations jumped 704.8% in 2022, then tumbled 2056.16% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 4040000.0 in 2021, then jumped by 704.8% to 24434000.0 in 2022, then slumped by 60.93% to 9547000.0 in 2023, then slumped by 239.24% to 13293000.0 in 2024, then tumbled by 83.25% to 24359000.0 in 2025.
- Business Quant data shows CELUW's Income from Continuing Operations at 24359000.0 in Q4 2025, 23076000.0 in Q3 2025, and 24524000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Celularity | - | - | -3.27 Mn | -24.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.36 Mn |
| Sep 30, 2025 | -23.08 Mn |
| Jun 30, 2025 | -24.52 Mn |
| Mar 31, 2025 | -19.75 Mn |
| Dec 31, 2024 | -13.29 Mn |
| Sep 30, 2024 | -16.10 Mn |
| Jun 30, 2024 | -6.49 Mn |
| Mar 31, 2024 | -22.01 Mn |
| Dec 31, 2023 | 9.55 Mn |
| Sep 30, 2023 | -93.88 Mn |
| Jun 30, 2023 | -47.95 Mn |
| Mar 31, 2023 | -64.02 Mn |
| Dec 31, 2022 | 24.43 Mn |
| Sep 30, 2022 | 4.80 Mn |
| Jun 30, 2022 | 47.83 Mn |
| Mar 31, 2022 | -62.87 Mn |
| Dec 31, 2021 | -4.04 Mn |
| Sep 30, 2021 | 49.94 Mn |
| Jun 30, 2021 | -64.52 Mn |
| Mar 31, 2021 | -81.50 Mn |